← back to search

Hatim Husain

UC San Diego Health System · US
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, and Molecular Biology Techniques and Applications.
h-index
32
citations
7,462
works
178
NIH funding
primary concept
email

Recent publications

Single-cell and spatial analysis reveals macrophage-T cell crosstalk in non-small cell lung cancer immunosuppression
Translational Lung Cancer Research 2025cited by 5position: middledoi
Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer
Cancer Treatment Reviews 2025cited by 4position: middledoi
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
Cancer 2025cited by 2position: middledoi
Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Clinical Cancer Research 2024cited by 85position: lastdoi
Proceedings of the 1st biannual bridging the gaps in lung cancer conference
The Oncologist 2024cited by 1position: middledoi
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
JTO Clinical and Research Reports 2023cited by 38position: middledoi
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
Translational Lung Cancer Research 2023cited by 19position: middledoi
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
JCO Precision Oncology 2022cited by 97position: firstdoi
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
JTO Clinical and Research Reports 2022cited by 38position: middledoi
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
npj Precision Oncology 2021cited by 65position: lastdoi
RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies
Frontiers in Genetics 2021cited by 32position: lastdoi
High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.
Journal of Clinical Oncology 2020cited by 24position: middledoi
Genome-wide cell-free DNA fragmentation in patients with cancer
Nature 2019cited by 1,440position: middledoi
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Cancer Research 2019cited by 237position: lastdoi
Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer
EBioMedicine 2019cited by 108position: middledoi
Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer
International Journal of Cancer 2019cited by 88position: middledoi
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
JAMA Oncology 2018cited by 685position: middledoi
<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Journal of Clinical Oncology 2018cited by 466position: middledoi
Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
Cancer Research 2018cited by 105position: lastdoi
Direct detection of early-stage cancers using circulating tumor DNA
Science Translational Medicine 2017cited by 1,144position: middledoi
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Nature Genetics 2017cited by 577position: middledoi
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine
Clinical Cancer Research 2017cited by 130position: firstdoi
Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
Molecular Cancer Therapeutics 2017cited by 101position: firstdoi
Cancer DNA in the Circulation
JAMA 2017cited by 93position: firstdoi
Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations
Sarcoma 2017cited by 65position: middledoi
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
Oncotarget 2017cited by 55position: middledoi
Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
Clinical Cancer Research 2016cited by 151position: middledoi
An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition
Nature Cell Biology 2014cited by 371position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Heather A. Wakelee · Stanford University5 papers (2018–2024)Brian Woodward · University of California San Diego5 papers (2017–2021)Joel W. Neal · Stanford Medicine4 papers (2018–2023)Zofia Piotrowska · Harvard University4 papers (2018–2023)Scott M. Lippman · Center for Personalized Cancer Treatment4 papers (2014–2019)Geoffrey R. Oxnard · Boston Medical Center3 papers (2018–2024)Razelle Kurzrock · Froedtert Hospital3 papers (2016–2017)Jacqueline V. Aredo · Stanford University3 papers (2020–2023)Lecia V. Sequist · Harvard University3 papers (2018–2022)Julia Rotow · Harvard University3 papers (2020–2023)Alona Muzikansky · Harvard University3 papers (2018–2022)Helena A. Yu · University of California, San Diego3 papers (2018–2022)Ajaz Bulbul · Oncology Specialists3 papers (2017–2019)Andrew J. Piper‐Vallillo · Lahey Medical Center3 papers (2020–2023) · 2 papers (2020–2022)Matthew A. Gubens · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2023–2024)Joshua Bauml · National Cancer Center2 papers (2020–2022)Tina Cascone · The University of Texas MD Anderson Cancer Center2 papers (2014–2024)Rebecca S. Heist · Harvard University2 papers (2020–2022)Parissa Keshavarzian · University of California San Diego2 papers (2018–2019)